Hypertensive Anaphylaxis in the Emergency Department: A Case Series
Abstract
Anaphylaxis is a rapid-onset, life-threatening allergic reaction that classically presents with hypotension and distributive shock. Hypertension is generally considered atypical in this context and may delay recognition of anaphylaxis in the emergency department. However, case reports and small studies have described paradoxical "hypertensive anaphylaxis," with reported prevalence rates of up to 12.9%. Awareness of this variant is essential to avoid withholding timely epinephrine therapy. We describe four adults who presented to the emergency department with systemic allergic reactions characterized by urticaria, angioedema, dyspnea, and gastrointestinal involvement. All four patients were initially normotensive but subsequently developed paradoxical hypertension, with blood pressures ranging from 140/90 mmHg to 168/102 mmHg at the time of anaphylaxis. Triggers included intravenous fluids, medications, and an insect bite. Each patient received intramuscular epinephrine (0.5 mg), intravenous fluids, corticosteroids, antihistamines, and inhaled bronchodilators where appropriate. Two patients required repeat epinephrine dosing for persistent symptoms. Despite presenting with elevated blood pressure, all patients tolerated epinephrine without any complications related to the catecholamine surge, such as arrhythmia, myocardial ischemia, or intracranial events. All recovered fully and were discharged after a short period of hospital observation. This case series reinforces that…
How strong is the evidence?
Evidence Hub reads this as a case series, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- Patient-Centered Pharmaceutical Design to Improve Acceptability of Medicines: Similarities and Differences in Paediatric and Geriatric Populations
- Evidence-based clinical practice guidelines for irritable bowel syndrome 2020
- Phase 2b Study of Pimodivir (JNJ-63623872) as Monotherapy or in Combination With Oseltamivir for Treatment of Acute Uncomplicated Seasonal Influenza A: TOPAZ Trial
- Gastrointestinal manifestations in COVID-19
- COVID-19 and Gastrointestinal Disease: Implications for the Gastroenterologist
- Persistent gut barrier damage and commensal bacterial influx following eradication of Giardia infection in mice
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.